title: [Efficiency of calcium and vitamin D3 in the treatment of steroid osteoporosis in patients with hormone dependent bronchial asthma].
abstract: OBJECTIVE
  To study effects of calcium (1000 mg/day) and vitamin D3 (Calcium-D3 Nikomed, 400 IN/day) in the treatment of steroid osteoporosis.
  
  
  METHODS
  Calcium-D3 Nikomed was used in combined treatment of 20 patients with hormone-dependent bronchial asthma (BA) receiving glucocorticoid tablets in daily dose 5-40 mg (prednisolone calculation), mean dose 20.4 mg. Density of bone tissue was measured by CT of the lumbar spine (L2-L4), concentrations of osteocalcine and 25 (OH) vitamin D3--by radioimmunoassay, serum and 24-h urine calcium--by atomic-absorption spectrophotometry and selective ionometry.
  
  
  RESULTS
  Calcium-D3 Nikomed intake for 6 months (2 tablets a day) resulted in decline of ossalgia, inhibition of bone tissue density loss, elevation of D3 vitamin 25 (OH) concentration in blood serum. Concentrations of osteocalcine, blood and 24-h urine calcium were close to the baseline. Therapeutic effect of physiological doses of vitamin D3 may be due to normalization of cholecalcipherol metabolism, activation of calcium intestinal absorption and suppression of bone resorption entailed by long-term administration of glucocorticoid tablets.
  
  
  CONCLUSIONS
  High clinical efficiency and absence of side effects recommend calcium-D3 Nikomed for management of steroid osteoporosis in patients with hormone-dependent bronchial asthma.
authors.forename: A V
authors.initials: AV
authors.lastname: Ememl'ianov
authors.forename: S E
authors.initials: SE
authors.lastname: Shevelev
authors.forename: B A
authors.initials: BA
authors.lastname: Murzin
authors.forename: V I
authors.initials: VI
authors.lastname: Amosov
mesh_terms: D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D002112:Calcifediol / Q000097:blood; D002118:Calcium / Q000097:blood / Q000652:urine; D002119:Calcium Carbonate / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D011239:Prednisolone / Q000009:adverse effects*; D011863:Radioimmunoassay; D013054:Spectrophotometry, Atomic; D019966:Substance-Related Disorders; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D005938:Glucocorticoids; D015675:Osteocalcin; D002762:Cholecalciferol; D011239:Prednisolone; D002119:Calcium Carbonate; D002112:Calcifediol; D002118:Calcium